Literature DB >> 8082316

The reliability of highly elevated CA 19-9 levels.

B R Osswald1, F E Klee, S Wysocki.   

Abstract

CA 19-9 is used as a tumour marker of the upper gastrointestinal tract. However, extremely elevated CA 19-9 levels are found also in patients with benign diseases. Cholestasis was present in 97.1% of patients with high elevated CA 19-9, independent of their primary disease. 50% of patients with non-malignant diseases and increased CA 19-9 levels showed liver cirrhosis, cholecystitis, pancreatitis and/or hepatitis. In 8.8% no explanation was found for the extremely high CA 19-9 level. The results provide evidence of different factors influencing the CA 19-9 level.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8082316     DOI: 10.1155/1993/234238

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  7 in total

1.  Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer.

Authors:  Mehmet Kiliç; Erdal Göçmen; Mesut Tez; Tamer Ertan; Mehmet Keskek; Mahmut Koç
Journal:  Can J Surg       Date:  2006-08       Impact factor: 2.089

2.  CA 19-9 to rule out pancreatic or biliary cancer among patients with cholestasis: an unsuitable test?

Authors:  Salvatore Madonia; Emma Aragona; Simonetta Maisano; Luigi Montalbano; Mirko Olivo; Francesca Rossi; Gaetano Restivo; Mario Cottone
Journal:  Dig Dis Sci       Date:  2007-03-07       Impact factor: 3.199

3.  False-positive findings for tumor markers after curative gastrectomy for gastric cancer.

Authors:  Takao Ohtsuka; Seiji Sato; Yoshihiko Kitajima; Masayuki Tanaka; Yuji Nakafusa; Kohji Miyazaki
Journal:  Dig Dis Sci       Date:  2007-05-03       Impact factor: 3.199

4.  The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis.

Authors:  Maximilian Schöniger-Hekele; Christian Müller
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

5.  Different roles of tumor marker monitoring after curative resections of gastric and colorectal cancers.

Authors:  Takao Ohtsuka; Yuji Nakafusa; Seiji Sato; Yoshihiko Kitajima; Masayuki Tanaka; Kohji Miyazaki
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

6.  The Prognostic Value of the CA19-9/TBIL Ratio in Patients with Biliary Tract Cancers (BTCs): A Retrospective Study.

Authors:  Jianchun Xiao; Li Wang; Tao Hong; Binglu Li; Wei Liu; Qiang Qu; Chaoji Zheng; Xiaodong He
Journal:  J Oncol       Date:  2021-02-23       Impact factor: 4.375

7.  Laparoscopic splenic total cystectomy in a patient with elevated CA 19-9.

Authors:  Melih Paksoy; Ilhan Karabicak; Ramazan Kusaslan; Suleyman Demiryas; Fadil Ayan; Metin Ertem
Journal:  JSLS       Date:  2006 Oct-Dec       Impact factor: 2.172

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.